Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-12-18
2007-12-18
Chen, Stacy B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S204100
Reexamination Certificate
active
10484298
ABSTRACT:
The invention concerns novel immunogenic peptides derived from the RSV G protein of the sub-group A or B comprising at least: a first peptide derived from the BRSV G protein of sub-group A or B including at least in position 173, 176, 182 and 186 a cysteine and whereof the C-terminal end includes at most the amino acid in position 192; and a second peptide derived from the RSV protein of sub-group A or B, said second peptide being located downstream of said first protein, so that the immunogenic peptide produced has a disulphide bond linking residues 173 and 186 and a second disulphide bond linking residues 176 and 182.
REFERENCES:
patent: 5223254 (1993-06-01), Paradiso et al.
patent: WO 8704185 (1987-07-01), None
patent: WO95/27787 (1995-10-01), None
patent: WO 9527787 (1995-10-01), None
patent: WO9527787 (1995-10-01), None
patent: WO 9746581 (1997-12-01), None
patent: WO 9903987 (1999-01-01), None
patent: WO 9949892 (1999-10-01), None
patent: WO 0121203 (2001-03-01), None
patent: WO0121203 (2001-03-01), None
Sparer et al., J. Exp. Med. 1998, 187(11):1921-1926.
Johnson et al., PNAS USA, 1987, 84:5625-5629.
David King, et al.: Expression, purification and characterization of B72.3 Fv fragments, Biochem. J. (1993) 290, p. 723-729.
Geoffery E. Scopes, et al.: Identification of a linear epitope on the fusion glycoprotein of respiratory syncytial virus, Journal of General Virology (1990), 71, p. 53-59.
Peter C. Fusco, et al.: Preclinical evaluation of novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. The Journal of Infectious Diseases, (1997), 175, pp. 364-372.
S. Croft, et al.: TraT: A powerful carrier molecule for the stimulation of immune responses to protein and peptide antigens, The Journal of Immunology, Feb. 1, 1991, vol. 146, No. 3, p. 793-798.
Simard C., et al.: Subgroup specific protection of mice from respiratory syncytial virus infection with peptides encompassing the amino acid region 174-187 form the G glycoprotein: the role of cycteinyl residues in protection, VACCINE vol. 15, No. 4, 1997 pp. 423-432.
Von Hunolstein C., et al. : The adjuvant effect of synthetic oligodexoynucleotide containing CpG motif converts the anti-haemophilus type b glycoconjugates into efficient anti-polysaccharides and a anto-carrier polyvalent vaccines, VACCINE, vol. 19, No. 23/24, Apr. 30, 2001, pp. 3058-3066.
A. Mountain, et al.: Engineering antibodies for therapy, Biotechnology and Genetic Engineering Reviews, vol. 10, Dec. 1992, p. 1-142.
Hyun Vha Kim, et al. : Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection, Pediat. Res., 10: pp. 75-78, 1976.
Steven Varga, et al. : The attachment (G) Glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 DC4+ T cell responses 1, Journal of Immunology, 165: p. 6487-6495, 2000.
Peter Olins, et al.: Recent advances in heterologous gene expression inEscherichia coli, Current Opinion in Biotechnology, vol. 4: 520-525, 1993.
Temple Smith, et al.: Comparison of Biosequences, Advances in Applied Mathematics, vol. 2: 482-489, 1981.
Saul Needleman, et al. : A general method applicable to the search for similarities in the amino acid sequence of two proteins, J. Mol. Biol., vol. 48: 443-453, 1970.
William Pearson, et al.: Improved tools for biological sequence comparison, Proc. Natl. Acad. Sci. USA, Vo. 85 p. 2444-2448, Apr. 1988.
Michel Trudel, et al.: Identification of a synthetic peptide as part of a major neutralization epitope of respiratory syncytial virus, J. gen. Virol., vol. 68 p. 2273-2280, 1987.
Michel Trudel, et al.: Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization, Can. J. Microbiol., vol. 33, 1987.
Juan Lopez, et al.: Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial virus, Journal of Virology, p. 927-930, Feb. 1990.
Philip Vella, et al.: Immunogenicity of conjugate vaccines consisting o pneumococcal capsular polysaccharide types 6B, 14, 19F and 23F and a meningococcal outer membrane protein complex, Infection and Immunity, p. 4977-4983, Dec. 1992.
Jean-Francois Haeuw, et al.: The recombinantklebsiella pneumoniaeouter membrane protein OmpA has carrier properties for conjugated antigenic peptides, Eur. J. Biochem, vol. 255, p. 446-454, 1998.
Helene Plotnicky-Gilquin, et al.: Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein, Journal of Virology, p. 5637-5645, Jul. 1999.
David Goeddel, Gene expression technology, Methods in Enzymology, vol. 185 TOC (1990).
G. Kohler: Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol. 256, Aug. 7, 1975.
Arne Skerra, et al.: Assembly of a functional immunoglobulin F, Fragment inEscherichia coli, Science, Vo. 240, p. 1038-1041, May 1988.
H. Mario Geysen, et al.: Strategies for epitope analysis using peptide synthesis, Journal of Immunological Methods, vol. 102, p. 259-174, 1987.
Paul Carter, et al.: Humanization of an anti-p185HER2antibody for human cancer therapy, Proc. Natl. Acad. Sic. USA, vol. 89, p. 4285-4289, May 1992.
Jurgen Doreleijers, et al.: Solution structure of the immunodominant region of protein G of bovine respiratory syncytial virus, Biochemistry, vol. 35, p. 14684-14688, 1996.
Beck Alain
Corvaia Nathalie
Ngoc Thien Nguyen
Plotnicky Hélène
Chen Stacy B.
Hueschen and Sage
Pierre Fabre Medicament
LandOfFree
Peptides of the respiratory syncytial virus (RSV) G protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides of the respiratory syncytial virus (RSV) G protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides of the respiratory syncytial virus (RSV) G protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3879415